SCHEMBL24820161

SCHEMBL24820161

CC(C)CN[C@H]1CCC[C@H]1O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.36
HTT P42858 1/20 0.36
EPHX1 P07099 1/20 0.35
SLC6A4 P31645 2/20 0.34
SLC6A3 Q01959 2/20 0.34
GLB1 P16278 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
CD274 Q9NZQ7 2/20 0.33
PDCD1 Q15116 1/20 0.33
ANPEP P15144 1/20 0.33
ERAP2 Q6P179 1/20 0.33
PDCD1LG2 Q9BQ51 1/20 0.32
LTA4H P09960 2/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MGAM O43451 2/20 0.31
SI P14410 2/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24842080 1.00 HTR1A (0.36) HTR1AHTTEPHX1SLC6A4SLC6A3
SCHEMBL27281293 1.00 HTR1A (0.36) HTR1AHTTEPHX1SLC6A4SLC6A3
SCHEMBL27281292 1.00 HTR1A (0.36) HTR1AHTTEPHX1SLC6A4SLC6A3
SCHEMBL24819140 0.96 HTT (0.40) HTR1AHTTEPHX1SLC6A4SLC6A3
SCHEMBL24819143 0.96 HTT (0.40) HTR1AHTTEPHX1SLC6A4SLC6A3
SCHEMBL21618648 0.96 HTT (0.40) HTR1AHTTEPHX1SLC6A4SLC6A3
SCHEMBL24819131 0.96 HTT (0.40) HTR1AHTTEPHX1SLC6A4SLC6A3
SCHEMBL24819149 0.96 HTT (0.40) HTR1AHTTEPHX1SLC6A4SLC6A3
SCHEMBL24818643 0.86 GLB1 (0.35) HTTEPHX1GLB1
SCHEMBL24819138 0.86 GLB1 (0.35) HTTEPHX1GLB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024081311-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2024-04-18 WO disclosed
US-20230212155-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. 2023-07-06 US disclosed
WO-2022272248-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2022-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212155-A1 PD-1/PD-L1 INHIBITORS PDCD1, CD274, PDCD1LG2 HTR1A 3777/4885HTT 4390/4885EPHX1 2907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.